lorviqua
pfizer europe ma eeig - lorlatinib - karcinóm, pľúc bez malých buniek - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
orserdu
stemline therapeutics b.v. - elacestrant - neoplazmy prsníkov - endokrinná terapia - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
erlotinib teva b.v. 150 mg
teva b.v., holandsko - erlotinib - 44 - cytostatica
erlotinib teva b.v. 100 mg
teva b.v., holandsko - erlotinib - 44 - cytostatica
erlotinib stada 150 mg
stada arzneimittel ag, nemecko - erlotinib - 44 - cytostatica
erlotinib stada 100 mg
stada arzneimittel ag, nemecko - erlotinib - 44 - cytostatica
erlotinib teva 150 mg filmom obalené tablety
teva pharmaceuticals slovakia s.r.o., slovensko - erlotinib - 44 - cytostatica
erlotinib teva 100 mg filmom obalené tablety
teva pharmaceuticals slovakia s.r.o., slovensko - erlotinib - 44 - cytostatica
erlotinib zentiva 150 mg
zentiva, k.s., Česká republika - erlotinib - 44 - cytostatica
erlotinib zentiva 100 mg
zentiva, k.s., Česká republika - erlotinib - 44 - cytostatica